Drug Trial Radar · NCT03216343
Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Nov 9, 2017
Primary completion
Nov 4, 2022
Study completion May 15, 2023
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Conditions
- Small Cell Lung Cancer
Interventions
ChiauranibDrug
CS2164
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective reponse rate(ORR)Time frame: Up to a minimum 24 weeks after the last participant's first dose, or progression, or 75% subjects died.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.